1. What Sanofi might buy with its Regeneron windfall — Gilead pens $2B Arcus pact for immuno-oncology targets — FDA approves BMS Opdivo + Yervoy combo for first-line on certain types of NSCLC — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Vascular Solutions Division - which is more entertaining?

Discussion in 'Teleflex Medical' started by anonymous, Jan 19, 2019 at 1:35 PM.

  1. anonymous

    anonymous Guest

    Our quality Management, Back Orders, or the Mass Exodus...
     
  2. anonymous

    anonymous Guest

    something tells me you suck at your job. Everyone has backorders. Selling vascular is easy if your competent.